Majority of therapies against MDM2 focus on either 1) inhibiting the MDM2-p53 interaction, 2) downregulating MDM2 expression, and 3) inhibiting its E3 ligase activity and its interaction with the proteasome to reduce p53 degradation and activate p53-dependent tumor suppressor pathways (Figure 5; Table 1). The gene discussed is TP53; the disease is neoplasm.